|
article
Mitch Dowsett and Michael Baum seem to be two of the foremost researchers specializing in the hormonal treatment of cancer--Here it is:
Annals of Oncology Advance Access originally published online on February 23, 2006
Annals of Oncology 2006 17(5):818-826; doi:10.1093/annonc/mdl016
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
M. Dowsett1,*, J. Houghton2, C. Iden2, J. Salter1, J. Farndon3, R. A'Hern4, R. Sainsbury5 and M. Baum6
1 Academic Department of Biochemistry, The Royal Marsden NHS Trust, London; 2 Clinical Trials Group of the Department of Surgery, Royal Free and University College Medical School, University College London, London; 3 University Department of Surgery, Bristol Royal Infirmary, Bristol; 4 Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, Surrey; 5 Department of Surgery, University College, London; 6 The Portland Hospital, London, UK
|